Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

NCT ID: NCT03643965

Last Updated: 2024-12-03

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

365 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-05

Study Completion Date

2023-07-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall aim of the study is to evaluate the efficacy, safety, and tolerability of Nefecon 16 mg per day in the treatment of patients with primary IgAN (Immunoglobulin A nephropathy) at risk of progressing to end-stage renal disease (ESRD), despite maximum tolerated treatment with renin-angiotensin system (RAS) blockade using angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II type I receptor blockers (ARBs).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of oral Nefecon compared to matching placebo in patients with primary IgAN on a background of optimized RAS inhibitor therapy. The study will consist of 2 parts, Part A and Part B. Part A will include a 9 month blinded Treatment Period, and a 3-month Follow up Period. Part B of the study will consist of a 12-month observational Follow up Period; no study drug will be administered during Part B. Part A and B will be blinded. Safety will be monitored by an independent Data Safety Monitoring Board.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary IgA Nephropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nefecon

Nefecon 16 mg once daily by mouth for 9 months.

Group Type EXPERIMENTAL

Nefecon

Intervention Type DRUG

Nefecon 16 mg for daily administration by mouth for 9 months.

Placebo oral capsule

Placebo oral capsule once daily by mouth for 9 months.

Group Type PLACEBO_COMPARATOR

Placebo oral capsule

Intervention Type DRUG

Placebo capsules for daily administration by mouth for 9 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nefecon

Nefecon 16 mg for daily administration by mouth for 9 months.

Intervention Type DRUG

Placebo oral capsule

Placebo capsules for daily administration by mouth for 9 months.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Budesonide modified released capsule Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Female or male patients ≥18 years
2. Biopsy-verified IgA nephropathy
3. Stable dose of RAS inhibitor therapy (ACEIs and/or ARBs) at the maximum allowed dose or Maximum Tolerated Dose (MTD) according to the 2012 KDIGO (Kidney Disease: Improving Global Outcomes) guidelines
4. Urine protein creatinine ratio ≥1 g/24hr
5. eGFR ≥35 mL/min per 1.73 m2 and ≤90 mL/min per 1.73 m2 using the Chronic Kidney Diseae Epidemiology Collaboration (CKD-EPI) formula
6. Willing and able to give informed consent

Exclusion Criteria

1. Systemic diseases that may cause mesangial IgA deposition.
2. Patients who have undergone a kidney transplant.
3. Patients with acute or chronic infectious disease including hepatitis, tuberculosis, human immunodeficiency virus (HIV), and chronic urinary tract infections.
4. Patients with liver cirrhosis, as assessed by the Investigator.
5. Patients with a diagnosis of type 1 or type 2 diabetes mellitus which is poorly controlled.
6. Patients with history of unstable angina, class III or IV congestive heart failure, and/or clinically significant arrhythmia, as judged by the Investigator;
7. Patients with unacceptable blood pressure control defined as a blood pressure consistently above national guidelines for proteinuric renal disease, as assessed by the Investigator
8. Patients with diagnosed malignancy within the past 5 years.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Calliditas Therapeutics AB

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Krassimir Mitchev, MD

Role: STUDY_DIRECTOR

Calliditas AB

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham, 1720 2nd Ave South

Birmingham, Alabama, United States

Site Status

Univ of Arizona, 1501 N Campbell Ave

Tucson, Arizona, United States

Site Status

Stanford University Medical Center, 777 Welch Rd

Palo Alto, California, United States

Site Status

Los Angeles Biomedical Research Institute at HUMC, 1124 W. Carson Street

Torrance, California, United States

Site Status

University of Colorado Health Science Center, 1200 East 19th Av.

Aurora, Colorado, United States

Site Status

Western Nephrology and Metabolic Bone Disease, PC-Westerminster, 8410 Decatur St.

Westminster, Colorado, United States

Site Status

Yale University School of Medicine, 330 Cedar Street

New Haven, Connecticut, United States

Site Status

Washington Nephrology Associates-Washington DC, 730 24th Street NW

Washington D.C., District of Columbia, United States

Site Status

University of Florida-Gainesville

Gainesville, Florida, United States

Site Status

Omega Research Maitland, 7912 Forest City Rd.

Orlando, Florida, United States

Site Status

Omega Research Maitland

Orlando, Florida, United States

Site Status

Northwestern University the Feinberg School of Medicine, 633 North St. Clair

Chicago, Illinois, United States

Site Status

Northshore University Health System, 2650 Ridge Av.

Evanston, Illinois, United States

Site Status

University of Kentucky Medical Center, 800 Rose St, Pavillion H 3rd floor

Lexington, Kentucky, United States

Site Status

University of Louisville-Nephrology

Louisville, Kentucky, United States

Site Status

Kidney Care and Transplant Services of New England, PC, 354 Birnie Av.

Springfield, Massachusetts, United States

Site Status

University of Minnesota, 717 Delaware St. SE

Minneapolis, Minnesota, United States

Site Status

Clinical Research Consultants, LLC, 3930 Washington St

Kansas City, Missouri, United States

Site Status

Queens Hospital Centre

Jamaica, New York, United States

Site Status

Icahn School of Medicine at Mount Sinai-James J. Peters VA Medical Center, One Gustave L. Levy Place

New York, New York, United States

Site Status

Columbia Univ Medical Center, Div of Nephrology, 51 Audubon Av

New York, New York, United States

Site Status

Mountain Kidney & Hypertension Assoc, 10 McDowell St

Asheville, North Carolina, United States

Site Status

University of North Carolina at Chapel Hill, Clinical & Translational Research Centre

Chapel Hill, North Carolina, United States

Site Status

Southeastern Nephrology-Whiteville, 800 Jefferson St

Whiteville, North Carolina, United States

Site Status

Southeastern Nephrology Associates-Wilmington, 1302 Medical Center Drive

Wilmington, North Carolina, United States

Site Status

Cleveland Clinic, Glickman Urological & Kidney Institute, 9500 Euclid Av.

Cleveland, Ohio, United States

Site Status

The Ohio State University (OSU), Wexner Medical Center, 410 West 10th Av.

Columbus, Ohio, United States

Site Status

Oregon Health & Science University, 3181 SW Sam Jackson Park Rd

Portland, Oregon, United States

Site Status

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Thomas Jefferson University, 211 S. 9th Street

Philadelphia, Pennsylvania, United States

Site Status

Allegheny General Hospital, 4800 Friendship Av.

Pittsburgh, Pennsylvania, United States

Site Status

Nephrology Associates, P.C., 28 White Bridge Rd

Nashville, Tennessee, United States

Site Status

Renal Disease Research Institute, 1250 Eighth Av. #135

Fort Worth, Texas, United States

Site Status

University of Vermont

Burlington, Vermont, United States

Site Status

Hospital Britanico de Buenos Aires, Pedriel 74

Capital Federal, , Argentina

Site Status

Clinica Priv Velez Sarsfield

Córdoba, , Argentina

Site Status

Hospital Privado-Centro Medico de Cordoba, Naciones Unidas 346, Nefrologia piso 1

Córdoba, , Argentina

Site Status

Sanatorio Allende, Hipolito Yrigoyen 384, 2 Piso

Córdoba, , Argentina

Site Status

Hospital Universitario Austral, Unidad de Investigacion Clinica, Av. J.D. Peron 1500, piso 4

Pilar, , Argentina

Site Status

Clinico de Nefrologia, Urologia Y Enfermedades Cardiovasculares, Av. Gdor Freyre 3074

Santa Fe, , Argentina

Site Status

Monash Medical Centre

Clayton, Victoria, Australia

Site Status

Royal Adelaide Hospital, Port Rd.

Adelaide, , Australia

Site Status

Box Hill Hospital, Dept of Renal Medicine, Arnold Str 5

Box Hill, , Australia

Site Status

Austin Health, Dept of Nephrology, 145 Studley Rd.

Heidelberg, , Australia

Site Status

Melbourne Health, Royal Melbourne Hospital, Dept of Nephrology,Grattan Str.

Parkville, , Australia

Site Status

Prince of Wales Hospital, Nephrology Dept, Parkes 3 West

Randwick, , Australia

Site Status

Western Health, Western Hospital-Sunshine Hospital, 176 Furlong Rd, Level 3, WHCRE Building

St Albans, , Australia

Site Status

Westmead Hospital, Dept of Renal Medicine, Hawkesbury Rd.

Westmead, , Australia

Site Status

Metro South Hospital and Health Service via Princess Alexandra Hospital, Dept of Nephrology, 199 Ipswich Rd.

Woolloongabba, , Australia

Site Status

Brest Regional Hospital, 7 Meditsinskaya str.

Brest, , Belarus

Site Status

Grodno Regional Clinical Hospital, 52 Bulvar Leninskogo Komsomola

Grodno, , Belarus

Site Status

Gomel Regional Clinical Hospital, 5 Brat'ev Lizukovyh str.

Homyel, , Belarus

Site Status

4-th N.E. Savchenko City Clinical Hospital, 110, R. Luxemburg str.

Minsk, , Belarus

Site Status

University Hospital Erasmus (Brussels), Recherche Clinique Nephrologie Transplantation, Route de Lennik 808

Brussels, , Belgium

Site Status

Cliniques Universitaires Saint-Luc, Nephrology Dept, Av. Hippocrate 10

Brussels, , Belgium

Site Status

University Hospital Gent, Dept of Medical Nephrology, Corneel Heymanslaan 10

Ghent, , Belgium

Site Status

Centre Hospitalier Universitaire de Liege, Nephrology Dept. Domaine Universitaire de Sart-Tilman

Liège, , Belgium

Site Status

AZ Delta, Wilgenstraat 2

Roeselare, , Belgium

Site Status

Royal Inland Hospital, Kidney Clinic, 7 South, 311 Columbia Street

Kamloops, British Columbia, Canada

Site Status

Interior Health-Kelowna General Hosp (IH KGH), 2268 Pandosy Str.

Kelowna, British Columbia, Canada

Site Status

Vancouver Coastal Health Authority, Gordon and Leslie Diamond Health Care Centre, 5 th floor, Diamond Building

Vancouver, British Columbia, Canada

Site Status

Queen Elizabeth II Health Sciences Centre, 1276 South Park St

Halifax, Nova Scotia, Canada

Site Status

Kingston General Hospital

Kingston, Ontario, Canada

Site Status

Hospital Maisonneuve-Rosemont, CNIB 3rd Floor, 1929 Bayview Avenue

Toronto, Ontario, Canada

Site Status

Toronto General Hospital, University Health Network, 200 Elizabeth St, 8 N-849

Toronto, Ontario, Canada

Site Status

CISSS de la Monteregie-Centre-Hopital Charles LeMoyne, Room E-304, 3120 Taschereau Blvd

Greenfield Park, Quebec, Canada

Site Status

CHUQ-L'Hotel Dieu de Quebec, 11 côte du Palais

Québec, Quebec, Canada

Site Status

Centre Hospiitalier Universitaire de Sherbrooke (CHUS), 3001, 12e Avenue Nord

Sherbrooke, Quebec, Canada

Site Status

Fakultni nemocnice Brno, Interni gastroenterologicka klinika, Jihlavska 20

Brno, , Czechia

Site Status

Fakultni nemocnice Hradec Kralove, Sokolska 581

Hradec Králové, , Czechia

Site Status

Fakultni nemocnice Olomouc, I.P. Pavlova 185/6

Olomouc, , Czechia

Site Status

Fakultni nemocnice Kralovske Vinohrady, Linterni klinika, Srobarova 1150/50

Prague, , Czechia

Site Status

Vseobecna fakultni nemocnice v Praze, Klinik nefrologie, U Nemocnice 499/2

Prague, , Czechia

Site Status

Helsinki University Central Hospital (HUCH), Nephrology Clinic, Meilahti Triangle Hospital

Helsinki, , Finland

Site Status

Study Cor Oy, Hoitajantie 4

Jyväskylä, , Finland

Site Status

Tampere University Hospital, P O Box 2000, Munuaiskeskus, Erakennus, 1. kerros

Tampere, , Finland

Site Status

Centre Hospitalier Boulogne sur Mer, 4eme etage Batiment Administratif, Allee Jacques Monod

Boulogne-sur-Mer, , France

Site Status

CHU Grenoble-Hopital Michallon, Service Nephrologie-Hemodialyse-Aphereses-Transplantation Renale, Boulevard de la Chantourne CS 10217

Grenoble, , France

Site Status

Lapeyronie Hospital, Univ Hospital Montpellier, 371 Av. du Doyen Gaston Giraud

Montpellier, , France

Site Status

Hopital Bichat-Claude Bernard, Service de Nephrologie, 46 rue Henri Huchard

Paris, , France

Site Status

Chu St Etienne-Hopital Nord, Service de Nephrologie Dialyse Transplantation renale, Av. Albert Raimond

Saint-Priest-en-Jarez, , France

Site Status

Centre Hospitalier de Valenciennes, Service de Nephrologie-Medecine Interne, Av. Desandrouin BP 379

Valenciennes, , France

Site Status

Uniklinik RWTH Aachen, Medizinische Klinik II, Pauwelsstrasse 30

Aachen, , Germany

Site Status

Universitaetsklinikum Carl Gustav Carus Dresden, Medizinische Klinik III, Nephrologie, Fetscherstr. 74

Dresden, , Germany

Site Status

Universitaetsklinikum Erlangen, Medizinisches Klinik 4, Ulmenweg 18

Erlangen, , Germany

Site Status

Universitaetsklinikum Heidelberg-Nephrologie, Renal Clinic, Im Neuenheimer Feld 162

Heidelberg, , Germany

Site Status

Universitatsklinik Schleswig-Holstein-Campus Lubek, Medizinische Klinik I, Nephrologie, Ratzeburger Allee 160

Lübeck, , Germany

Site Status

University Clinic Munich, LMU-Inner City Medical Polyclinic, Nephrologisches Zentrum, Medizinische Klinik und Poliklinik IV

Munich, , Germany

Site Status

Universitaetsklinikum Regensburg, Abteilung für Nephrologie, Franz-Josef-Strauss Allee 11

Regensburg, , Germany

Site Status

General Hospital of Athens-Laiko, Nephrology Clinic, 17 Agiou Thoma Street

Athens, , Greece

Site Status

University Hospital of Heraklion, Nephrology Clinic, Diastaurosi Staurakion-Vouton

Heraklion, , Greece

Site Status

University General Hospital of Ioannina, Nephrology Clinic, Leof. Stavros Niarchou

Ioannina, , Greece

Site Status

University Hospital of Larissa Medical School, Nefrology Clinic, Mezourlo

Larissa, , Greece

Site Status

General Hospital of Nikaia Ag. Panteleimon, Nephrology Clinic, Mantouvalou 3 Str.

Nikaia, , Greece

Site Status

University General Hospital of Patras, Rio

Pátrai, , Greece

Site Status

Hippokration General Hosp of Thessaloniki, Nephrology Clinic, 49 Konstantinoupoleos Str

Thessaloniki, , Greece

Site Status

Azienda Ospedale Policlinico di Bari

Bari, , Italy

Site Status

ASST di Lecco, Presidio Ospedaliero Alessandro Manzoni, Via dell´Eremo 9/11

Lecco, , Italy

Site Status

Ospedale San Carlo Borromeo, Via Pio II, 3

Milan, , Italy

Site Status

Istituti Clinici Scientifici Maugeri Spa-Societa Benefit, Div. di Nephrologia ed Emodialist, Via S. Maugeri 10

Pavia, , Italy

Site Status

Uniwersyteckie Centrum Kliniczne-Szpital Gdanskiego Uniwersytetu Medycznego

Gdansk, , Poland

Site Status

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Centralny Szpital Kliniczny, Uniwersytetu Medycznego w Lodzi, ul Pomorska 251

Lodz, , Poland

Site Status

Wojewodzki Szpital Specjalistyczny w Olsztynie, Oddzial Kliniczny Nefrologiczny, Hipertensjologii i Chorob Wewnetrznych, ul. Zolnierska 18

Olsztyn, , Poland

Site Status

Sonomed Sp. z.o.o. ul. Bandurskiego 98/U12

Szczecin, , Poland

Site Status

Dong-A University Hospital, Won Suk An, 26 Daesingongwon-Ro Seogu

Busan, , South Korea

Site Status

Kyungpook National University Hospital, 130 Dongdeok-ro Jung-gu

Daegu, , South Korea

Site Status

Chungnam National University Hospital, 282 Munhwa-ro, Jung-gu

Daejeon, , South Korea

Site Status

Hallym University Sacred Heart Hospital,22 Gwanpyeong-ro 170 beon-gil, Dongan-gu, Anyang-si

Gyeonggi-do, , South Korea

Site Status

Seoul National University Hospital, 101 Daehak-Ro, Jongno-Gu

Seoul, , South Korea

Site Status

Seoul St. Mary´s Hospital, 222 Banpo-Daero, Seocho-gu

Seoul, , South Korea

Site Status

Chung-Ang University Hospial, 102 Heukseok-ro, Dongiak-gu

Seoul, , South Korea

Site Status

Hospital Universitario Fundacion Alcorcon, C/Budapest 1

Alcorcón, , Spain

Site Status

Hospital del Mar, Passeig Maritim 25-29

Barcelona, , Spain

Site Status

Hospital Universitario Vall d´Hebron, Passeig Vall d´Hebron 119-129

Barcelona, , Spain

Site Status

Hospital Clinic Barcelona, Escalera 12, Planta 5, Calle Villaroel 170

Barcelona, , Spain

Site Status

Hospital Universitari Arnau de Vilanova, Avenida Alcalde Rovire Roure 80

Lleida, , Spain

Site Status

Hospital General Universitario Gregorio Maranon, Servicio de Nefrologica, C/Dr. Esquerdo 46

Madrid, , Spain

Site Status

Hospital 12 de Octubre, Residencia General (Sotano 1)-Area de Ensayos Clinicos, Avda. Cordoba s/n

Madrid, , Spain

Site Status

Sahlgrenska University Hospital, Njurmottagningen, Vita Stråket 12

Gothenburg, , Sweden

Site Status

Universitetssjukhuset Linköping, Njurmedicinska kliniken

Linköping, , Sweden

Site Status

Karolinska University Hospital-Huddinge, Njur-KBC M87

Stockholm, , Sweden

Site Status

Danderyds sjukhus, Njurmedicinska kliniken

Stockholm, , Sweden

Site Status

Uppsala University Hospital, Dept of Nephrology, ing 30, plan 5

Uppsala, , Sweden

Site Status

Kaohsiung Medical Univ Chung-Ho Memorial Hospital

Kaohsiung City, , Taiwan

Site Status

China Medical University Hospital, No 2 Yude Rd

Taichung, , Taiwan

Site Status

Taichung Veterans General Hospital

Taichung, , Taiwan

Site Status

National Cheng Kung University Hospital, No 138 Sheng Li Rd

Tainan City, , Taiwan

Site Status

Cukurova University Medical Faculty, Dept of Internal Disease, Div of Nephrology, Balcali

Adana, , Turkey (Türkiye)

Site Status

Istanbul University Cerrahpasa, Medical Faculty-Dept of Internal Disease, Fatih-Cerrahpasa, Kocamustafapasa Caddesi No 53

Istanbul, , Turkey (Türkiye)

Site Status

Ege University Med Faculty Dept of Internal Disease, Div of Nephrology

Izmir, , Turkey (Türkiye)

Site Status

Erciyes University Faculty of Medicine,Semiha Kibar Organ Nakli ve Dyaliz Hastanesi, Kosk Mah. prof dr Turhan Feyziogly Cad. no 42

Kayseri, , Turkey (Türkiye)

Site Status

Kocaeli University Medical School-Internal Medicine, Nephrology, Umuttepe Yerleskesi

Kocaeli, , Turkey (Türkiye)

Site Status

Belfast City Hospital, 51 Lisburn Rd

Belfast, , United Kingdom

Site Status

Southmead Hospital, Southmead Rd, Westbury-on-Trym

Bristol, , United Kingdom

Site Status

Queen Elizabeth University Hosp-Glasgow, Glasgow Clin Research Facility 5th floor, Institute of Neurosciences

Glasgow, , United Kingdom

Site Status

Gloucestershire Royal Hospital, Great Western Rd

Gloucester, , United Kingdom

Site Status

St James´s University Hospital, Beckett St.

Leeds, , United Kingdom

Site Status

Leicester General Hospital, John Walls Renal Unit, Gwendolen Rd

Leicester, , United Kingdom

Site Status

The Royal London Hospital, Whitechapel

London, , United Kingdom

Site Status

University of Manchester, Manchester Royal Infirmary, Oxford Rd

Manchester, , United Kingdom

Site Status

Nottingham City Hospital, Hucknall Rd

Nottingham, , United Kingdom

Site Status

Northern General Hospital, Herries Rd.

Sheffield, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Belarus Belgium Canada Czechia Finland France Germany Greece Italy Poland South Korea Spain Sweden Taiwan Turkey (Türkiye) United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Fellstrom BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sorensen SS, Tesar V, Del Vecchio L; NEFIGAN Trial Investigators. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017 May 27;389(10084):2117-2127. doi: 10.1016/S0140-6736(17)30550-0. Epub 2017 Mar 28.

Reference Type BACKGROUND
PMID: 28363480 (View on PubMed)

Zhang H, Lafayette R, Wang B, Ying L, Zhu Z, Stone A, Kristensen J, Barratt J. Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results. Kidney360. 2024 Dec 1;5(12):1881-1892. doi: 10.34067/KID.0000000583. Epub 2024 Oct 9.

Reference Type DERIVED
PMID: 39724565 (View on PubMed)

Lafayette R, Kristensen J, Stone A, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J; NefIgArd trial investigators. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023 Sep 9;402(10405):859-870. doi: 10.1016/S0140-6736(23)01554-4. Epub 2023 Aug 14.

Reference Type DERIVED
PMID: 37591292 (View on PubMed)

Liao J, Zhou Y, Xu X, Huang K, Chen P, Wu Y, Jin B, Hu Q, Chen G, Zhao S. Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review. Front Immunol. 2023 Jan 4;13:926517. doi: 10.3389/fimmu.2022.926517. eCollection 2022.

Reference Type DERIVED
PMID: 36685528 (View on PubMed)

Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19.

Reference Type DERIVED
PMID: 36270561 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Nef-301

Identifier Type: -

Identifier Source: org_study_id